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Background: Delirium is a frequently misdiagnosed and inadequately treated neuropsychiatric complication most
commonly observed in terminally ill cancer patients. To our knowledge this is the first report describing delirium in
two patients aged less than 60 years and enrolled in an intensive chemotherapeutic protocol for acute
promyelocytic leukemia.
Case presentation: Two female Caucasian acute promyelocytic leukemia patients aged 46 and 56 years developed
delirium during their induction treatment with all-trans retinoic acid and idarubicin. In both cases symptoms were
initially attributed to all-trans retinoic acid that was therefore immediately suspended. In these two patients several
situations may have contribute to the delirium: in patient 1 a previous psychiatric disorder, concomitant treatments
with steroids and benzodiazepines, a severe infection and central nervous system bleeding while in patient 2
steroid treatment and isolation. In patient 1 delirium was treated with short-term low-doses of haloperidol while
in patient 2 non-pharmacologic interventions had a beneficial role. When the diagnosis of delirium was clear,
induction treatment was resumed and both patients completed their therapeutic program without any relapse of
the psychiatric symptoms. Both patients are alive and in complete remission as far as their leukemia is concerned.
Conclusions: We suggest that patients with acute promyelocytic leukemia eligible to intensive chemotherapy
should be carefully evaluated by a multisciplinary team including psychiatrists in order to early recognize symptoms
of delirium and avoid inadequate treatments. In case of delirium, both pharmacologic and non-pharmacologic
interventions may be considered.
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Delirium is a disturbance of consciousness characterized
by changes in cognition, perceptual disturbances and a
reduced ability to focus, sustain, or shift attention. These
symptoms occur over a short period of time and tend to
fluctuate during the course of the day [1]. Delirium is
the most frequent neuropsychiatric complication in ter-
minally ill cancer patients with a prevalence of up to
85% in the last weeks of life [2]. Even though delirium is
associated with a significant morbidity and mortality, it
is frequently underdiagnosed or misdiagnosed and there-
fore inadequately treated [2].* Correspondence: gm.rigolin@ospfe.it
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reproduction in any medium, provided the orIn hematologic patients, delirium has been mainly ob-
served in elderly cases not eligible for intensive chemo-
therapeutic regimens [3] and in subjects undergoing
myeloablative hematopoietic stem-cell transplantation,
with a prevalence of nearly 50% during the 4 weeks after
conditioning and stem-cell infusion [4].
In adults, acute promyelocytic leukemia (APL) is the
most curable subtype of acute myeloid leukemias. APL
is frequently considered a medical emergency because of
its life threatening coagulation complications [5] that re-
quire immediate treatment with both all-trans retinoic
acid (ATRA)-based therapies and measures to counter-
act the coagulopathy [6].
In this report we present two APL patients aged less
than 60 years who developed delirium in the early
phases of their induction treatment with ATRA and
idarubicin. In both cases, the symptoms were initiallyLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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However subsequently, in both cases a diagnosis of de-
lirium was made and the treatment for APL was there-




Misses G, a 46-year-old married Caucasian woman, was
admitted in October 2010 to our hematology unit for
bleeding signs (petecchiae, hematomas), pancytopenia
(white blood cell count 0.24 × 103/μL, hemoglobin
6.6 g/dL, platelet count 35 × 103/μL) with normal pro-
thrombin time (PT) and activated partial thrombo-
plastin time (APTT) coagulation tests but a slightly
reduced fibrinogen level (113 mg/dL) and increased
D-Dimer (2017 ng/mL: normal value < 370). In ado-
lescence she had a history of eating disorder. Bone
marrow aspirate showed 90% of hypergranular blasts
expressing the following markers: myeloperoxidase,
CD13 and CD33. CD34 and HLA-DR were instead not
expressed on blast cells. Cytogenetic analysis showed
the classical translocation t(15;17)(q22;q21) [7]. A diag-
nosis of APL was therefore made. At diagnosis computed
tomography (CT) and magnetic resonance imaging (MRI)
scans showed the presence of 2 small hemorrhagic le-
sions in the suprachiasmatic region and in the right
cerebellum. Neurologic examination was normal. The
patient immediately started an induction therapy with
ATRA (45 mg/m2/day) and idarubicin (12 mg/m2 on
days 2-4-6-8). Prednisone (0.5 mg/kg/day) was given to
prevent differentiation syndrome [6]. After 7 days of
treatment the patient exhibited difficulty in focusing
attention, anxiety, hyperpnoea, restlessness and irrit-
ability. In the suspect of differentiation syndrome,
ATRA was suspended, while steroids were adminis-
tered at therapeutic dosage (dexamethasone 8 mg
intravenous every 12 hours) along with a concomitant
treatment with oral benzodiazepine for the state of
anxiety. In the following 10 days the patient showed a
progressive worsening of her psychological status with
disorientation, disorganized thinking, misperceptions,
hallucinations, severe neurological abnormalities in-
cluding tremor, dysgraphia, apraxia, aphasia. At this
point, according to the Diagnostic and Statistical Man-
ual of Mental Disorders, 4th Edition (DSM-IV) criteria
as previously described [8], a diagnosis of mixed hyper-
active and hypoactive delirium was made and treat-
ment with haloperidol (0.5 mg per os or intravenous
every 12 hours) was started, while lorazepam 0.5 mg
intravenous was used in case of agitation. ATRA
administration was resumed. In the following days the
patient worsened because of sepsis by Enterecoccus
faecalis and subsequent pneumonitis that requiredantibiotics. The clinical course of the delirium showed
a consensual worsening characterized by profound
lethargy with an Eastern Cooperative Oncology Group
(ECOG) performance status of 4 (totally confined to
bed) requiring parenteral feeding and supportive care.
After 30 days from the beginning of induction treat-
ment the patient showed hematologic recovery which
anticipated a progressive improvement of her clinical
and psychiatric picture. After 25 days of treatment
haloperidol was stopped. A rehabilitative program was
begun and she was finally dismissed in complete
hematologic response after 64 days. She was subse-
quently readmitted to our unit to complete, without
further significant clinical problems, the therapeutic
protocol which included 3 consolidation chemothera-
peutic regimens. The patient is now alive and well, in
complete remission after 2 years from diagnosis.
Case 2
Misses S, a 56-year-old married Caucasian woman, was
admitted in July 2012 to our hematology unit for
bleeding signs (petecchiae, hematomas), pancytopenia
(white blood cell count 0.55 × 103/μL, hemoglobin
7.6 g/dL, platelet count 47 × 103/μL) with normal
fibrinogen level and APTT, increased PT (1.46 INR), and
increased D-Dimer (7496 ng/mL: normal value < 370).
Bone marrow aspirate showed 95% of hypergranular
myeloperoxidase positive, CD13 positive, CD33 nega-
tive, HLA-DR negative and CD34 negative blasts with
cytogenetic analysis demonstrating the translocation
t(15;17)(q22;q21), thus confirming the diagnosis of
APL. The patient immediately started induction ther-
apy including ATRA (45 mg/m2/day for 28 days) and
idarubicin (12 mg/m2 on days 2-4-6-8). Prednisone
(0.5 mg/kg/day) was given to prevent differentiation
syndrome. During this period the patient was in
isolation in a positive-pressure ventilated room. After
8 days of treatment the patient showed agitation, eu-
phoria, altered perceptions including misperceptions,
illusions, acoustic hallucinations. ATRA was tempo-
rarily suspended and steroids were administered at
higher levels (dexamethasone 8 mg intravenous every
12 hours). Since CT scan, lumbar puncture and audio-
logical evaluation were all negative, a diagnosis of
hyperactive delirium was made according to DSM-IV
criteria as previously described [8]. After 4 days of
suspension, ATRA treatment was therefore resumed,
steroids were tapered, while for her delirium non-
pharmacologic interventions were adopted including
environmental family support and reallocation in a
double room. Thereafter the patient progressively
recovered from her psychological status, completed
induction treatment. She was finally dismissed after
35 days in complete hematologic response with a
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patient subsequently completed 3 consolidation courses of
chemotherapy and is now in complete remission. No re-
lapse of delirium was observed in the subsequent readmis-
sions to the clinic.
Conclusions
In advanced cancer patients, delirium is often associ-
ated with a poor prognosis, although 50% of patients
can improve with appropriate management of contrib-
uting etiologies. Early recognition of delirium and
treatment are therefore important in diminishing mor-
bidity and mortality [2].
In patients with cancer, delirium can result either
from a direct effect of the cancer on the central ner-
vous system (CNS) or from indirect CNS effects related
to the clinical course of the disease (ie, older age, elec-
trolyte imbalance, dehydration, major organ failures,
infections, vascular complications, para-neoplastic syn-
dromes, border line cognitive impairment) [9]. Che-
motherapeutic and immunotherapeutic agents (i.e.;
vincristine, corticosteroids, interferon) and medica-
tions used in supportive care (i.e., opioids, benzodiaze-
pines, hypnotics, antidepressant, antiemetics) may
contribute to delirium in these patients [10]. Accord-
ing to the level of psychomotor activity, three clinical
delirium subtypes have been described: hypoactive,
hyperactive, and mixed (with alternating features of
both hyperactive and hypoactive delirium) [2]. The
hypoactive subtype is characterized by psychomotor
retardation, lethargy, and reduced awareness of sur-
roundings. The hyperactive subtype is commonly char-
acterized by restlessness, agitation, hyper-vigilance,
hallucinations, and delusions. Hypoactive delirium is
often mistaken for depression and is difficult to differ-
entiate from pharmacological sedation, or obtundation
in the last days of life.
To our knowledge this is the first report describing
delirium in APL patients aged less than 60 years and
enrolled in an intensive chemotherapeutic regimen. In
our two cases several situations that could have precip-
itated the psychiatric status were present: in patient 1 a
previous psychiatric disorder, concomitant treatments
with steroids and benzodiazepines, a severe infection
and CNS bleeding while in patient 2 we could annotate
steroid treatment and isolation. It is important that
clinicians include delirium as a possible complication
in the treatment of APL patients eligible for intensive
regimens and that they consider concomitant clinical
conditions or medications that may precipitate this
condition. This is critical in order to avoid a misdiag-
nosis that may lead to the suspension of APL treatment
resulting in a reduced response rate. However, psy-
chiatrists asked to consult on patients being treatedfor APL should also be aware that the symptoms of dif-
ferentiation syndrome, a complication occurring in up
to 25% of these cases, may also be misinterpreted as a
primary psychiatric disorder [11].
In cancer patients with delirium both pharmacologic
and non-pharmacologic interventions can be used [9].
Pharmacologic interventions include short-term low-
dose of antipsychotics, with close monitoring for
possible adverse effects, particularly in patients with mul-
tiple medical comorbidities. However, non-pharmacologic
interventions also appear to have a beneficial role in
the treatment of cancer patients with delirium. Based
on the evidence from non-oncology settings, it is
strongly recommended to implement non-pharmacologic
interventions in patients with delirium or at risk for de-
lirium since no serious complications have been ob-
served with a non-pharmacologic strategy [9].
In conclusion, we believe that patients with APL eli-
gible for intensive chemotherapeutic regimens should
be carefully evaluated by a multisciplinary team includ-
ing psychiatrists in order to early recognize delirium
symptoms and avoid inadequate treatments. In case of
delirium, both pharmacologic and non-pharmacologic
interventions may be considered.
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